37 results about "Cyclin-dependent kinase 4" patented technology

The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.

This invention is in the area of tricyclic lactam compounds, compositions and methods of protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, protection of healthy cells is disclosed using compounds that act as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.

Novel pyrazolopyrimidines of formula (I):

are discussed. These pyrazolopyrimidines are capable of inhibiting the activity of cyclin-dependent kinases, most particularly cyclin-dependent kinase 1 (Cdk1), cyclin-dependent kinase 2 (Cdk2), and cyclin-dependent kinase 4 (Cdk4) and are thus useful, inter alia, in the treatment or control of cancer, in particular solid tumors. This invention also provides pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors.

The invention relates to a novel synthesis method of a CDK4 (cyclin-dependent kinase 4) inhibitor. A reaction of 2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one with acetylchloride is taken as an initial reaction, consequent reactions are performed, and the CDK4 inhibitor is prepared; the preparation method is simple and easy to implement, the yield is high, the quality is high, and industrial production is facilitated.

A combination of a CDK4/8 inhibitor and an mTOR inhibitor for the treatment of cancer.

The invention relates to application of a pyrilamine compound as a cycle protein dependency kinase 4/6 inhibitor. The compound is of a structure shown as formula (I), preferably, wherein R1 and R2 are respectively hydrogen, hydroxyl or alkyl, and X is halogen. More preferably, R1 is hydrogen or hydroxyl, R2 is alkyl, X is fluorine, chlorine or bromine; and particularly preferably, R1 is hydrogen, R2 is methyl, ethyl, propyl, isopropyl, normal-butyl, isobutyl or tertiary butyl, and X is fluorine.

The invention discloses a compound to induce degradation of CDK4/6 (cyclin dependent kinase 4/6) based on CRBN (cereblon) ligand. A compound shown as formula I and a pharmaceutically acceptable salt and hydrate thereof are included herein. The invention also discloses a preparation method of the compound, a pharmaceutical composition of the compound, and application of the compound and the pharmaceutical composition in the preparation of drugs to prevent or/and treat cancers. Degradation of CDK4/6 can be induced just with a low quantity of the compound, and toxic and side effects upon the human body can be alleviated; excellent CDK4/6 degrading action and anticancer activity can be exhibited; the anticancer effect is better than that of a CDK4/6 inhibitor; the compound herein is suitable for preventing or/and treating various cancers and has a great application prospect in the field of medicine.

The invention relates to the field of pharmaceutical chemistry, and discloses a beta-carboline alkaloid represented by formula (I), and an application thereof in the preparation of antitumor drugs. The beta-carboline alkaloid has an inhibition effect on cyclin-dependent kinase 4, can be used to prepare the antitumor drugs, and provides more medicine choices for tumor treatment.

The invention belongs to the technical field of pharmaceutical compounds and particularly relates to a deuterated palbociclib derivative and preparation method and application thereof; the deuterated palbociclib derivative has a structure shown as in formula (I); by selectively deuterating active metabolic sites of palbociclib, the metabolic nature of a pharmaceutical is improved, and the therapeutic effect, safety and durability of the pharmaceutical are improved accordingly; through the synthesis of the deuterated palbociclib derivative, a novel compound is provided for synthesizing a novel antitumor pharmaceutical; this compound is applicable to the inhibitor pharmaceutical aspect to inhibit cyclin dependent kinase 4 and/or 6, and the aspect of pharmaceuticals for treating breast cancer, ovarian cancer, liver cancer or acute lymphoblastic leukemia.

The invention provides a deuterated Palbociclib crystal shown in the formula I and a preparation method and pharmaceutical application thereof and particularly relates to a deuterated Palbociclib crystal shown in the formula I, a preparation method of the crystal, a crystal composition containing the crystal, a pharmaceutical composition containing the crystal and the crystal composition thereof and pharmaceutical application of the crystal and the crystal composition thereof. The crystal has the advantages of being high in purity and crystallinity, good in stability and easy to prepare, and can be used for preparing medicine for treating diseases caused by cyclin dependent kinase 4 and 6. The formula I is shown in the specification.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio)), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; and/or treating a subject suffering from ER mutant expressing breast cancer, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

The invention provides a crystallization, preparation method and medical application of a deuteration Palbociclib isethionate as shown in the formula I and particularly relates to the crystallization of the deuteration Palbociclib isethionate shown in equation I, a preparation method of the crystal, the crystal compositions containing the crystal, the medicine compositions containing the crystal and the crystal compositions, and the medical application of the crystal and the crystal compositions. The crystal has the advantages of having high purity and high crystallinity, having good stability and being easy to prepare. The crystal can be adopted for the preparation of drugs for the treatment of the diseases caused by cyclin dependent kinase 4 and 6. Please see the formula in the description.

The present invention concerns an in vitro assay for determining the activation status of endogenous CDK4 in eukaryotic cells, said assay comprising the steps of: providing eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form; inducing proliferation of said eukaryotic cells; isolating the cyclin D/CDK4 fusion protein from said eukaryotic cells; and measuring the activation status of said isolated cyclin D/CDK4 fusion protein, thereby determining the activation stats of endogenous CDK4 in said eukaryotic cells.

The invention relates to an antitumor human single-chain antibody, which belongs to a human antibody, in particular to a specific anti-human D1-cyclin-dependent kinase 4 (CDK4) human single-chain antibody which has a nucleotide sequence represented by a Sequence No.1. The antitumor human single-chain antibody also comprises genetic coding sequence of nuclear localization signal (NLS) peptide and an E-tag peptide, and the nucleotide sequence of the genetic coding sequence is represented by a Sequence No.2. The invention also relates to the use of the antitumor human single-chain antibody in the preparation of antitumor medicines, wherein the tumors treated are human breast cancer and human cervical carcinoma. The invention antitumor human single-chain antibody is a low-toxicity, high-efficiency and specific molecule for inhibiting the activity of CDK4 and has the advantages of small molecular weight, low immunogenicity and the like. A tumor specific eukaryotic expression vector is usedto perform the tumor targeted treatment of the antibody and realize the controllability of the therapeutic gene, and the tumor specific eukaryotic expression vector has tumor specificity and therefore ensures treatment safety and effectiveness.